Outlook Therapeutics (OTLK) Non-Current Deffered Revenue (2015 - 2019)

Outlook Therapeutics (OTLK) has reported Non-Current Deffered Revenue for 5 consecutive years, with $3.5 million the latest figure, recorded in Q2 2019.

• In Q2 2019, Non-Current Deffered Revenue rose 15.41% year-over-year to $3.5 million; the TTM figure through Jun 2019 stood at $3.5 million (up 15.41% YoY), while the FY2018 annual figure was $2.8 million, down 38.25% from the prior year.
• Non-Current Deffered Revenue retreated to $3.5 million in Q2 2019 per OTLK's latest filing, from $4.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $12.7 million in Q3 2015 and bottomed at $2.8 million in Q3 2018.
• Historically, Non-Current Deffered Revenue has averaged $4.8 million across 5 years, with a median of $4.5 million in 2017.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue sank 59.51% — and 2019, when it rose 23.46%.
• Outlook Therapeutics' Non-Current Deffered Revenue stood at $12.7 million in 2015, then plunged by 61.89% to $4.9 million in 2016, then slipped by 16.87% to $4.0 million in 2017, then climbed by 16.58% to $4.7 million in 2018, then fell by 24.84% to $3.5 million in 2019.
• Business Quant data shows OTLK's Non-Current Deffered Revenue at $3.5 million in Q2 2019, $4.1 million in Q1 2019, and $4.7 million in Q4 2018.